Tehran University of Medical Sciences Iranian Journal of Psychiatry 1735-4587 6 4 2016 07 11 161 163 Nazir Hashemi Abad Department of Psychiatry, Faculty of Medicine, Yasouj University of Medical Science, Yasouj, Iran Najafi Shala Doulatabad Department of Nursing, College of Nursing & Midwifery, Yasouj University of Medical Science, Yasouj, Iran Ali Mohammadi Department of Psychiatry, Faculty of Medicine,Yasouj University of Medical Science, Yasouj, Iran Hamid Reza Ghafarian Srazi Department of Social Medicine, Faculty of Medicine; Yasouj University of Medical Sciences, Yasouj, IranDepartment of Epidemiology And Biostatistics, Tehran University of Medical Sciences, School of Public Health, Tehran, Iran 2015 10 14 Schizophrenia and various neurological disorders have some signs and symptoms. Visual hallucinations are one of such disorders. The related studies in some diseases for example Parkinson Disease and Lewy Body Dementia indicate that Acetylcholine (Ach) plays a significant role in neuropsychiatric manifestation and its association with visual hallucination; therefore, visual hallucinations occur due to the depletion of Ach. Drug therapies such as Cholinesterase inhibitors (ChEIs) for increasing Ach level may be beneficial in treating visual hallucination. AchEI's have been used in the treatment of visual hallucinations in Dementia and Parkinson's Disease. We thought that a similar Ach depletion may cause visual hallucinations in patients with schizophrenia and may provide a target for drug treatment. We had a patient with schizophrenia whose psychotic symptoms responded to the treatment plan, but her visual hallucination did not. However, the patient's visual hallucination successfully responded to Rivastigmine (AchEI).This case illustrates the use of an AchEI in the treatment of refractory visual hallucinations in a patient with schizophrenia. https://ijps.tums.ac.ir/index.php/ijps/article/view/239 https://ijps.tums.ac.ir/index.php/ijps/article/download/239/235